TransMedics Group, Inc. (NASDAQ:TMDX) management will conduct a conference call for 4th November 2020 at 4:30 PM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website www.transmedics.com
Earnings Expectation
TransMedics Group, Inc. is reporting third quarter financial results on Wednesday 4th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, TMDX is expected to report 3Q20 loss of $ 0.32 per share from revenue of $ 5.55 million.
For the full year, analysts anticipate top line of $ 24.77 million, while looking forward to loss of $ 1.42 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 40.00 million ~ $ 43.00 million
Click Here For More Historical Outlooks Of TransMedics Group, Inc.
Transmedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers.
